FreeTender
Accepting bidsgrantUnited States

Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional)

Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities

Published
19 Aug 2026
Closes
30 May 2029, 23:59 UTC
Reference
PAR-27-056
Location
United States
Sector
Healthcare & Pharma

Details

The Institutional Development Award (IDeA) program develops biomedical research capacity in states that have historically received low levels of NIH funding (IDeA states). The IDeA Clinical & Translational Research (CTR) program supports two programmatic tracks to build clinical and translational (C&T) research capacity to enable research on diseases and health challenges prevalent in IDeA states. IDeA CTR Development (CTR-D) awards focus on C&T research workforce development and infrastructure enhancement at health research organizations with limited clinical research capacity in IDeA states. IDeA CTR Network (CTR-N) awards support statewide (or multi-state) networks of health research organizations to expand existing infrastructure, develop the research workforce to enhance the network organization's ability to design and implement competitive C&T research programs, and coordinate clinical research activities state-wide and/or across IDeA states.This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered. Eligibility: Eligibility Criteria for Lead and Partner OrganizationsEvery organization in the application must be either a Lead or a Partner–no organization can be both.Every organization in the application must be in an IDeA-eligible state.There are strict limits to avoid overlap:Each IDeA-eligible state can only have one active IDeA-CTR-type (IDeA-CTR, CTR-N, or CTR-D) award at a time.An organization can only be involved in one IDeA-CTR-type award at a time.Organizations may not serve as a lead, partner or otherwise participate with an active Clinical and Translational Science Award (CTSA). Organizations must meet all eligibility rules at the time of application submission and award.Additional Eligibility Criteria for Lead OrganizationsTo apply as the lead, the organization must:Already have externally-funded clinical and translational (C&T) research.Additional Eligibility Criteria for Partner OrganizationsTo participate as a partner, the organization mustBe in the same state or multi-state region as the lead organization.Note:Active awards include awards in no-cost extension (NCE).An organization that currently leads an active IDeA-CTR-type award may submit a new application if substantial changes to the CTR are proposed. If the new application is funded, the current award will be administratively ended before the new award begins.

CFDA number(s): 93.859

Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.

Context for bidders

We hold 411 notices from National Institutes of Health, going back to May 2023 — 378 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 369 open Healthcare & Pharma tenders in United States. This one closes in 975 days.

Before you bid on this tender

A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.

  • Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
  • Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
  • Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
  • Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
  • Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
  • Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.

More Healthcare & Pharma tenders

All Healthcare & Pharma tenders →

FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.

Verify & apply on the official portal →